Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion

    Question

    CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion

    Direct answer

    CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-casgevy-sales-surge-78-qoq-to-76m-following-fda-expansion-54ee98

    POLICY
    CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
    CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
    CRSPVRTX
    Impact
    67
    SEP 9
    SIG
    85%
    CRSPVRTX
    CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
    CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
    → A 78% QoQ sales increase to $76M accelerates commercial royalty cash flows, expanding CRSP's addressable pediatric market.
    Impact
    CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
    Affected
    CRSPVRTX
    Transmission
    A 78% QoQ sales increase to $76M accelerates commercial royalty cash flows, expanding CRSP's addressable pediatric market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial cash flow expansion via gene therapy rampUp1-4wCasgevy revenue reached $76M, up 78% QoQ, following pediatric label expansion.
    VRTXco-development revenue sharingUp1-4wVertex co-commercializes Casgevy with CRISPR Therapeutics under existing profit-sharing agreement.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month